Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 585

1.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group.

Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.

PMID:
31813637
2.

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis.

López-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A.

RMD Open. 2019 Nov 21;5(2):e001108. doi: 10.1136/rmdopen-2019-001108. eCollection 2019.

3.

[Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Kiltz U, Braun J; DGRh, Becker A; DEGAM, Chenot JF, Dreimann M; DWG, Hammel L; DVMB, Heiligenhaus A; DOG, Hermann KG; DRG, Klett R; DGMM, Krause D, Kreitner KF, Lange U; DGPMR/DGRW, Lauterbach A; Physio Deutschland, Mau W, Mössner R; DDG, Oberschelp U; DGOOC, Philipp S, Pleyer U, Rudwaleit M, Schneider E, Schulte TL, Sieper J, Stallmach A; DGIM, Swoboda B; DGOOC/DGORh, Winking M; DGNC.

Z Rheumatol. 2019 Dec;78(Suppl 1):3-64. doi: 10.1007/s00393-019-0670-3. German. No abstract available.

PMID:
31784900
4.

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J.

Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.

PMID:
31732180
5.

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups.

Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.

6.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D.

Ann Rheum Dis. 2020 Jan;79(1):88-93. doi: 10.1136/annrheumdis-2019-216151. Epub 2019 Oct 29. Review.

7.

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.

Sieper J, Poddubnyy D, Miossec P.

Nat Rev Rheumatol. 2019 Dec;15(12):747-757. doi: 10.1038/s41584-019-0294-7. Epub 2019 Sep 24. Review.

PMID:
31551538
8.

[Pathogenesis of spondylarthritis : Relevance for treatment].

Sieper J, Poddubnyy D.

Z Rheumatol. 2020 Feb;79(1):5-12. doi: 10.1007/s00393-019-00708-y. Review. German.

PMID:
31506791
9.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
10.

Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis.

Proft F, Muche B, Spiller L, Rios Rodriguez V, Rademacher J, Weber AK, Lüders S, Protopopov M, Redeker I, Spiller I, Sieper J, Poddubnyy D.

Joint Bone Spine. 2020 Jan;87(1):69-73. doi: 10.1016/j.jbspin.2019.07.007. Epub 2019 Jul 29.

11.

[Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis].

Redeker I, Callhoff J, Hoffmann F, Saam J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Z Rheumatol. 2020 Feb;79(1):85-94. doi: 10.1007/s00393-019-0678-8. German.

PMID:
31359143
12.

Current Unmet Needs in Spondyloarthritis.

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2019 Jul 13;21(9):43. doi: 10.1007/s11926-019-0844-7. Review.

PMID:
31302784
13.

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.

Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A.

RMD Open. 2019 Jun 7;5(1):e000917. doi: 10.1136/rmdopen-2019-000917. eCollection 2019.

14.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

15.

[Health care and disease burden in persons with axial spondyloarthritis in Germany].

Haibel H, Redeker I, Zink A, Callhoff J, Marschall U, Hoffmann F, Sieper J, Poddubnyy D.

Z Rheumatol. 2019 Nov;78(9):865-874. doi: 10.1007/s00393-019-0650-7. German.

PMID:
31172266
16.

Peripheral spondyloarthritis: Concept, diagnosis and treatment.

Molto A, Sieper J.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):357-368. doi: 10.1016/j.berh.2019.02.010. Epub 2019 Mar 2. Review.

PMID:
31171308
17.

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis.

Llop M, Rios Rodriguez V, Redeker I, Sieper J, Haibel H, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2019 May 24;21(1):126. doi: 10.1186/s13075-019-1913-z.

18.

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

van Lunteren M, van der Heijde D, Sepriano A, Berg IJ, Dougados M, Gossec L, Jacobsson L, Ramonda R, Rudwaleit M, Sieper J, Landewé R, van Gaalen FA.

Rheumatology (Oxford). 2019 Sep 1;58(9):1649-1654. doi: 10.1093/rheumatology/kez095.

19.

Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1634-1638. doi: 10.1093/rheumatology/kez090.

PMID:
30903141
20.

Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis.

Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, Mansmann U, Rudwaleit M, Poddubnyy D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1556-1564. doi: 10.1093/rheumatology/kez025.

PMID:
30830164
21.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, Nurwakagari P, Weinman J.

RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019.

22.

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care.

Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, Rudwaleit M.

RMD Open. 2018 Dec 5;4(2):e000825. doi: 10.1136/rmdopen-2018-000825. eCollection 2018.

23.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
24.

Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study.

Greese J, Diekhoff T, Sieper J, Schwenke C, Makowski MR, Poddubnyy D, Hamm B, Hermann KGA.

J Rheumatol. 2019 Apr;46(4):376-383. doi: 10.3899/jrheum.171425. Epub 2019 Jan 15.

PMID:
30647167
25.

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.

Rios Rodriguez V, Hermann KG, Weiß A, Listing J, Haibel H, Althoff C, Proft F, Behmer O, Sieper J, Poddubnyy D.

Arthritis Rheumatol. 2019 May;71(5):722-728. doi: 10.1002/art.40786. Epub 2019 Mar 7.

PMID:
30625261
26.

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D; MEASURE 1 and MEASURE 2 study groups.

RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.

27.

Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis.

Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, Brandt-Jürgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, Köhler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hinüber U, Wagener P, Weidemann HF, Zinke S, Witte T.

Arthritis Rheumatol. 2019 May;71(5):729-735. doi: 10.1002/art.40777. Epub 2019 Mar 20.

PMID:
30418704
28.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
29.

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D.

Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29.

30.

An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.

Schulte-Wrede U, Sörensen T, Grün JR, Häupl T, Hirseland H, Steinbrich-Zöllner M, Wu P, Radbruch A, Poddubnyy D, Sieper J, Syrbe U, Grützkau A.

Arthritis Res Ther. 2018 Aug 29;20(1):191. doi: 10.1186/s13075-018-1692-y.

31.

Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study.

Diekhoff T, Greese J, Sieper J, Poddubnyy D, Hamm B, Hermann KA.

Ann Rheum Dis. 2018 Nov;77(11):1585-1589. doi: 10.1136/annrheumdis-2018-213393. Epub 2018 Aug 10.

PMID:
30097454
32.
33.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.

PMID:
29961640
34.

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ.

Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.

35.

Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno et al.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2019 Jun;78(6):e55. doi: 10.1136/annrheumdis-2018-213620. Epub 2018 May 31. No abstract available.

PMID:
29853451
36.

Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study.

Ziegeler K, Eshkal H, Schorr C, Sieper J, Diekhoff T, Makowski MR, Hamm B, Hermann KG.

J Rheumatol. 2018 Jul;45(7):915-921. doi: 10.3899/jrheum.170904. Epub 2018 Apr 15.

PMID:
29657142
37.

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

van der Heijde D, Sieper J, Maksymowych WP, Lambert RG, Chen S, Hojnik M, Anderson JK, Pangan AL.

Arthritis Res Ther. 2018 Mar 27;20(1):61. doi: 10.1186/s13075-018-1556-5.

38.

What low back pain is and why we need to pay attention.

Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M; Lancet Low Back Pain Series Working Group.

Lancet. 2018 Jun 9;391(10137):2356-2367. doi: 10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21. Review.

PMID:
29573870
39.

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.

Van den Bosch F, Mease PJ, Sieper J, Baeten DL, Xia Y, Chen S, Pangan AL, Song IH.

RMD Open. 2018 Feb 26;4(1):e000566. doi: 10.1136/rmdopen-2017-000566. eCollection 2018.

40.

Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2018 Jul;77(7):1017-1024. doi: 10.1136/annrheumdis-2017-212629. Epub 2018 Mar 10.

41.

Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research.

Dubreuil M, Sieper J.

Arthritis Rheumatol. 2018 Jul;70(7):981-983. doi: 10.1002/art.40462. Epub 2018 May 7. No abstract available.

42.

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.

Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.

J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166. Epub 2018 Feb 15.

PMID:
29449504
43.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.

RMD Open. 2017 Dec 28;3(2):e000592. doi: 10.1136/rmdopen-2017-000592. eCollection 2017.

44.

Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.

Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2018 Apr 1;57(4):703-711. doi: 10.1093/rheumatology/kex475.

PMID:
29373733
45.

Disease activity in ankylosing spondylitis: the global therapeutic target.

Wendling D, Prati C, Sieper J.

Ann Rheum Dis. 2018 Aug;77(8):1095-1096. doi: 10.1136/annrheumdis-2017-212363. Epub 2017 Dec 15. No abstract available.

PMID:
29247127
46.

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

Protopopov M, Sieper J, Haibel H, Listing J, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Oct 24;19(1):240. doi: 10.1186/s13075-017-1453-3.

47.

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

Poddubnyy D, Sieper J.

Rheumatology (Oxford). 2018 Jul 1;57(7):1145-1150. doi: 10.1093/rheumatology/kex361.

PMID:
29040753
48.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

PMID:
28811201
49.

Mechanism of New Bone Formation in Axial Spondyloarthritis.

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2017 Sep;19(9):55. doi: 10.1007/s11926-017-0681-5. Review.

PMID:
28752489
50.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

Supplemental Content

Loading ...
Support Center